OA
REGN icon

Oak Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Oak Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.16M Hold
10,560
– – 0.55% 39
2025
Q4 		$8.15M Buy
10,560
+70
+0.7% +$47.5K 0.49% 43
2025
Q3 		$5.9M Buy
10,490
+2,298
+28% +$1.3M 0.36% 46
2025
Q2 		$4.3M Sell
8,192
-1,640
-17% -$915K 0.28% 52
2025
Q1 		$6.24M Hold
9,832
– – 0.47% 44
2024
Q4 		$7M Sell
9,832
-55
-0.6% -$46.2K 0.48% 45
2024
Q3 		$10.4M Buy
9,887
+61
+0.6% +$67.9K 0.7% 37
2024
Q2 		$10.3M Hold
9,826
– – 0.69% 35
2024
Q1 		$9.46M Hold
9,826
– – 0.66% 40
2023
Q4 		$8.63M Hold
9,826
– – 0.65% 40
2023
Q3 		$8.09M Buy
9,826
+35
+0.4% +$27.5K 0.67% 39
2023
Q2 		$7.04M Sell
9,791
-2
-0% -$1.54K 0.56% 42
2023
Q1 		$8.05M Hold
9,793
– – 0.66% 41
2022
Q4 		$7.07M Buy
9,793
+5,881
+150% +$4.34M 0.59% 44
2022
Q3 		$2.69M Hold
3,912
– – 0.23% 63
2022
Q2 		$2.31M Buy
3,912
+337
+9% +$219K 0.18% 66
2022
Q1 		$2.5M Hold
3,575
– – 0.15% 72
2021
Q4 		$2.26M Hold
3,575
– – 0.12% 80
2021
Q3 		$2.16M Hold
3,575
– – 0.12% 77
2021
Q2 		$2M Hold
3,575
– – 0.11% 80
2021
Q1 		$1.69M Buy
3,575
+380
+12% +$185K 0.1% 86
2020
Q4 		$1.54M Buy
3,195
+195
+7% +$105K 0.09% 90
2020
Q3 		$1.68M Buy
3,000
+1,615
+117% +$979K 0.11% 78
2020
Q2 		$864K Buy
+1,385
New +$786K 0.06% 98

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Oak Associates's REGN Position: Q1 2026 in Review

Oak Associates held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 10,560 shares worth $8.16M. The position accounts for 0.55% of the portfolio, ranked #39.

Oak Associates first reported a position in REGN in Q2 2020 and has held it in 24 quarters since. The position peaked at $10.4M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Oak Associates held 10,560 shares of Regeneron Pharmaceuticals worth $8.16M as of Q1 2026.
  • Oak Associates left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.55% of Oak Associates's portfolio in Q1 2026, its #39 holding.
  • Oak Associates first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Oak Associates's Regeneron Pharmaceuticals position peaked at $10.4M in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Oak Associates's 13F filing for Q1 2026, filed 14 May 2026.